CoChat

Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor

Open access
Shraga, Amit, Olshvang, Evgenia, Davidzohn, Natalia, Khoshkenar, Payam, Germain, Nicolas, Shurrush, Khriesto, Carvalho, Silvia, Avram, Liat, Albeck, Shira, Unger, Tamar, Lefker, Bruce, Subramanyam, Chakrapani, Hudkins, Robert L., Mitchell, Amir, Shulman, Ziv, Kinoshita, Takayoshi, London, Nir · 2019 · Cell Chemical Biology
Cited by 64

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The c-Jun NH2-terminal kinase (JNK) signaling pathway is central to the cell response to stress, inflammatory signals, and toxins. While selective inhibitors are known for JNKs and for various upstream MAP3Ks, no selective inhibitor is reported for MKK7--one of two direct MAP2Ks that activate JNK. Here, using covalent virtual screening, we identify selective MKK7 covalent inhibitors. We optimized these compounds to low-micromolar inhibitors of JNK phosphorylation in cells. The crystal structure of a lead compound bound to MKK7 demonstrated that the binding mode was correctly predicted by docking. We asserted the selectivity of our inhibitors on a proteomic level and against a panel of 76 kinases, and validated an on-target effect using knockout cell lines. Lastly, we show that the inhibitors block activation of primary mouse B cells by lipopolysaccharide. These MKK7 tool compounds will enable better investigation of JNK signaling and may serve as starting points for therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2018.10.011

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 63

  1. Adams, 2016, Fragment-based drug discovery of potent and selective MKK3/6 inhibitors, Bioorg. Med. Chem. Lett., 26, 1086, 10.1016/j.bmcl.2015.11.054 · doi:10.1016/j.bmcl.2015.11.054
  2. Bubici, 2014, JNK signalling in cancer: in need of new, smarter therapeutic targets, Br. J. Pharmacol., 171, 24, 10.1111/bph.12432 · DOI · Paper page
  3. Chaikuad, 2018, The cysteinome of protein kinases as a target in drug development, Angew. Chem. Int. Ed., 57, 4372, 10.1002/anie.201707875 · DOI · Paper page
  4. Cohen, 2005, Structural bioinformatics-based design of selective, irreversible kinase inhibitors, Science, 308, 1318, 10.1126/science1108367 · DOI · Paper page
  5. Correy, 2017, Overcoming insecticide resistance through computational inhibitor design, bioRxiv
  6. Cuenda, 1998, Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1, Biochem. J., 333, 11, 10.1042/bj3330011 · DOI · Paper page
  7. Davies, 2012, Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies, Biochem. Soc. Trans., 40, 85, 10.1042/BST20110641 · DOI · Paper page
  8. Dhanasekaran, 2017, JNK-signaling: a multiplexing hub in programmed cell death, Genes Cancer, 8, 682, 10.18632/genesandcancer.155 · DOI · Paper page
  9. Egorina, 2006, In-cell western assay: a new approach to visualize tissue factor in human monocytes, J. Thromb. Haemost., 4, 614, 10.1111/j.1538-7836.2005.01781.x · DOI
  10. Emsley, 2004, Coot: model-building tools for molecular graphics, Biol. Crystallogr., 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
  11. Fabian, 2005, A small molecule-kinase interaction map for clinical kinase inhibitors, Nat. Biotechnol., 23, 329, 10.1038/nbt1068 · DOI · Paper page
  12. Flanagan, 2014, Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors, J. Med. Chem., 57, 10072, 10.1021/jm501412a · DOI · Paper page
  13. Fleming, 2000, Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7, Biochem. J., 352, 145, 10.1042/bj3520145 · DOI · Paper page
  14. Han, 2001, c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis, J. Clin. Invest., 108, 73, 10.1172/JCI12466 · DOI · Paper page
  15. Jaeschke, 2007, Metabolic stress signaling mediated by mixed-lineage kinases, Mol. Cell, 27, 498, 10.1016/j.molcel.2007.07.008 · DOI
  16. Kabsch, 2010, XDS, Acta Crystallogr. D Biol. Crystallogr., 66, 125, 10.1107/S0907444909047337 · DOI · Paper page
  17. Kathman, 2016, Covalent tethering of fragments for covalent probe discovery, Med. Chem. Commun., 7, 576, 10.1039/C5MD00518C · DOI
  18. Kinoshita, 2017, High-resolution structure discloses the potential for allosteric regulation of mitogen-activated protein kinase kinase 7, Biochem. Biophys. Res. Commun., 493, 313, 10.1016/j.bbrc.2017.09.025 · DOI
  19. Krenitsky, 2012, Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor, Bioorg. Med. Chem. Lett., 22, 1433, 10.1016/j.bmcl.2011.12.027 · DOI
  20. Lagoutte, 2017, Covalent inhibitors: an opportunity for rational target selectivity, Curr. Opin. Chem. Biol., 39, 54, 10.1016/j.cbpa.2017.05.008 · DOI · Paper page
  21. Lanning, 2014, A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors, Nat. Chem. Biol., 10, 1, 10.1038/nchembio.1582 · DOI · Paper page
  22. Lawler, 1998, Synergistic activation of SAPK1/JNK1 by two MAP kinase kinases in vitro, Curr. Biol., 8, 1387, 10.1016/S0960-9822(98)00019-0 · DOI · Paper page
  23. Leproult, 2011, Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors, J. Med. Chem., 54, 1347, 10.1021/jm101396q · DOI · Paper page
  24. Liu, 2013, Developing irreversible inhibitors of the protein kinase cysteinome, Chem. Biol., 20, 146, 10.1016/j.chembiol.2012.12.006 · DOI · Paper page
  25. Lomaga, 1999, TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling, Genes Dev., 13, 1015, 10.1101/gad.13.8.1015 · DOI · Paper page
  26. Mazzitelli, 2011, The loss of c-Jun N-terminal protein kinase activity prevents the amyloidogenic cleavage of amyloid precursor protein and the formation of amyloid plaques in vivo, J. Neurosci., 31, 16969, 10.1523/JNEUROSCI.4491-11.2011 · DOI
  27. Messoussi, 2014, Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents, Chem. Biol., 21, 1433, 10.1016/j.chembiol.2014.09.007 · DOI
  28. Minguet, 2008, Enhanced B-cell activation mediated by TLR4 and BCR crosstalk, Eur. J. Immunol., 38, 2475, 10.1002/eji.200738094 · DOI
  29. Morishima, 2001, Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand, J. Neurosci., 21, 7551, 10.1523/JNEUROSCI.21-19-07551.2001 · DOI · Paper page
  30. Müller, 2015, The ins and outs of selective kinase inhibitor development, Nat. Chem. Biol., 11, 818, 10.1038/nchembio.1938 · DOI · Paper page
  31. Murshudov, 2011, REFMAC 5 for the refinement of macromolecular crystal structures, Biol. Crystallogr., 67, 355, 10.1107/S0907444911001314 · DOI · Paper page
  32. Nelson, 2013, Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC, Onco Targets Ther., 6, 135
  33. Nnadi, 2018, Novel K-Ras G12C switch-II covalent binders destabilize ras and accelerate nucleotide exchange, J. Chem. Inf. Model., 58, 464, 10.1021/acs.jcim.7b00399 · DOI · Paper page
  34. Peng, 2013, Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors, J. Med. Chem., 56, 3889, 10.1021/jm400072p · DOI
  35. Regot, 2014, Resource high-sensitivity measurements of multiple kinase activities in live single cells, Cell, 157, 1724, 10.1016/j.cell.2014.04.039 · DOI · Paper page
  36. Roulston, 1998, Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha, J. Biol. Chem., 273, 10232, 10.1074/jbc.273.17.10232 · DOI · Paper page
  37. Roy, 2008, Role of the JNK signal transduction pathway in inflammatory bowel disease, World J. Gastroenterol., 14, 200, 10.3748/wjg.14.200 · DOI
  38. Sabapathy, 2012, Role of the JNK pathway in human diseases, Prog. Mol. Biol. Transl. Sci., 106, 145, 10.1016/B978-0-12-396456-4.00013-4 · DOI
  39. Schirmer, 2006, Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides, Proc. Natl. Acad. Sci. U S A, 103, 4234, 10.1073/pnas.0600445103 · DOI · Paper page
  40. Schramek, 2011, The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression, Nat. Genet., 43, 212, 10.1038/ng.767 · DOI
  41. Sogabe, 2015, 5Z-7-Oxozeaenol covalently binds to MAP2K7 at Cys218 in an unprecedented manner, Bioorg. Med. Chem. Lett., 25, 593, 10.1016/j.bmcl.2014.12.011 · DOI
  42. Sogabe, 2016, A crucial role of Cys218 in configuring an unprecedented auto-inhibition form of MAP2K7, Biochem. Biophys. Res. Commun., 473, 476, 10.1016/j.bbrc.2016.03.036 · DOI
  43. Tournier, 2001, MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines, Genes Dev., 15, 1419, 10.1101/gad.888501 · DOI · Paper page
  44. Ung, 2015, DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors, ACS Chem. Biol., 10, 269, 10.1021/cb500696t · DOI
  45. Ung, 2018, Redefining the protein kinase conformational space with machine learning, Cell Chem. Biol., 25, 10.1016/j.chembiol.2018.05.002 · DOI · Paper page
  46. Verma, 2012, The critical role of JNK in the ER-mitochondrial crosstalk during apoptotic cell death, J. Cell. Physiol., 227, 1791, 10.1002/jcp.22903 · DOI
  47. Volkamer, 2015, Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery, J. Chem. Inf. Model., 55, 538, 10.1021/ci500624s · DOI
  48. Wager, 2010, Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes, ACS Chem. Neurosci., 1, 420, 10.1021/cn100007x · DOI · Paper page
  49. Wang, 2007, Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease, Neurology, 69, 1480, 10.1212/01.wnl.0000277648.63931.c0 · DOI · Paper page
  50. Wang, 2012, Distinct signaling properties of mitogen-activated protein kinase kinases 4 (MKK4) and 7 (MKK7) in embryonic stem cell, J. Biol. Chem., 287, 2787, 10.1074/jbc.M111.281915 · DOI
  51. Ward, 2015, Structure-guided design of highly selective and potent covalent inhibitors of ERK1/2, J. Med. Chem., 58, 4790, 10.1021/acs.jmedchem.5b00466 · DOI
  52. Watanabe, 2017, Protein crystallography beamline BL2S1 at the Aichi synchrotron, J. Synchrotron Radiat., 24, 338, 10.1107/S1600577516018579 · DOI
  53. Weerapana, 2010, Quantitative reactivity profiling predicts functional cysteines in proteomes, Nature, 468, 790, 10.1038/nature09472 · DOI · Paper page
  54. Winn, 2011, Overview of the CCP 4 suite and current developments, Biol. Crystallogr., 67, 235, 10.1107/S0907444910045749 · DOI · Paper page
  55. Yarza, 2016, c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer’s disease, Front. Pharmacol., 6, 1, 10.3389/fphar.2015.00321 · DOI · Paper page
  56. Yazawa, 2003, CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes, Immunobiology, 102, 1374
  57. Zeke, 2016, JNK Signaling : Regulation and Functions Based on Complex Protein- Protein Partnerships, Microbiol. Mol. Biol. Rev., 80, 793, 10.1128/MMBR.00043-14 · DOI · Paper page
  58. Zhang, 2013, Discovery of potent and selective covalent inhibitors of JNK, Chem. Biol., 19, 140, 10.1016/j.chembiol.2011.11.010 · DOI · Paper page
  59. Zhao, 2014, The clinical development of MEK inhibitors, Nat. Rev. Clin. Oncol., 11, 385, 10.1038/nrclinonc.2014.83 · DOI · Paper page
  60. Zhao, 2018, Progress with covalent small-molecule kinase inhibitors, Drug Discov. Today, 23, 727, 10.1016/j.drudis.2018.01.035 · DOI · Paper page
  61. Zhao, 2017, Determining cysteines available for covalent inhibition across the human kinome, J. Med. Chem., 60, 2879, 10.1021/acs.jmedchem.6b01815 · DOI · Paper page
  62. Zhou, 2010, A structure-guided approach to creating covalent FGFR inhibitors, Chem. Biol., 17, 285, 10.1016/j.chembiol.2010.02.007 · DOI · Paper page
  63. Zhu, 2001, Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer’s disease, J. Neurochem., 76, 435, 10.1046/j.1471-4159.2001.00046.x · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Shraga, A., Olshvang, E., Davidzohn, N., Khoshkenar, P., Germain, N., Shurrush, K., Carvalho, S., Avram, L., Albeck, S., Unger, T., Lefker, B., Subramanyam, C., Hudkins, R. L., Mitchell, A., Shulman, Z., Kinoshita, T., & London, N.
Venue
Cell Chemical Biology
Publisher
Elsevier BV
Published
2019-01
Volume
26
Issue
1
Pages
98-108.e5
ISSN
  • 2451-9448 (ISSN-L)
  • 2451-9456
OpenAlex
W2900458600
Cited by
64
References
14
FWCI
5.15
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • Israel Science Foundation (1097/16)
  • German-Israeli Foundation (I-2483-302.5/2017)
  • Teva National Network of Neuroscience

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.